Daniel J. Peterson, MA, MS

Articles by Daniel J. Peterson, MA, MS

Quality Measurement of Medication Monitoring in the Meaningful Use Era

ByJennifer Tjia, MD, MSCE,Terry S. Field, DSc,Shira H. Fischer, AB,Shawn J. Gagne, BA,Daniel J. Peterson, MA, MS,Lawrence D. Garber, MD,Jerry H. Gurwitz, MD

September 7th 2011

Shifting from claims to integrated electronic health records to calculate quality metrics will improve reported quality attributable to data capture changes, not true quality improvements.

Latest Updated Articles

Quality Measurement of Medication Monitoring in the Meaningful Use Era
September 7th 2011

Daniel J. Peterson, MA, MS

Articles by Daniel J. Peterson, MA, MS

Quality Measurement of Medication Monitoring in the Meaningful Use Era

Latest Updated Articles

Trending on AJMC

First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy

Unanswered Questions in First- and Second-Line mCRC Care

Planning for Third-Line Therapy and Treatment Rechallenge in mCRC

Multidisciplinary Care for Vitiligo: Beyond Dermatology

Precision Drugs Meet Payer Realities

Delivering Cellular Therapy in Community Oncology: OHC’s Approach

Daniel J. Peterson, MA, MS

Articles by Daniel J. Peterson, MA, MS

Quality Measurement of Medication Monitoring in the Meaningful Use Era

Latest Updated Articles

Trending on AJMC

First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy

Unanswered Questions in First- and Second-Line mCRC Care

Planning for Third-Line Therapy and Treatment Rechallenge in mCRC

Multidisciplinary Care for Vitiligo: Beyond Dermatology

Precision Drugs Meet Payer Realities